.png){kind=icon}
.png){kind=icon}
Return
Precision targeting of CLDN18.2: A new therapeutic paradigm for gastric cancer
.png){kind=icon}
PRE
AI
W
W
C
DOI：10.1016/j.ctrv.2026.103176.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• CLDN18.2 as a novel therapeutic target in gastric cancer. • mAbs show promising efficacy in CLDN18.2-positive gastric cancer. • ADCs improve targeted drug delivery to CLDN18.2-expressing cells. • Bispecific antibodies and CAR-T therapies broaden CLDN18.2-directed options. • Resistance and toxicity remain key challenges in CLDN18.2 targeting.
Journal
IF:
10.5
Papers:
2.8K
Citations:
1.3W
Organization
Cited Papers